Accelmed

Accelmed is a private equity firm that specializes in growth-stage investments within the medical device sector. While sometimes described as a venture capital firm, Accelmed's strategy is more aligned with private equity, focusing on commercial-stage companies that have already demonstrated clinical efficacy and possess significant market potential. Established in 2009, the firm primarily targets businesses with proven technologies and products, aiming to create value through strategic guidance and operational support to accelerate their commercial expansion.

Since its inception, Accelmed has successfully raised over $500 million across multiple funds. Notably, their Accelmed Partners II, L.P. fund closed in 2017 with $180 million in commitments, followed by Accelmed Partners III, L.P., which secured $200 million in 2021. These substantial fund sizes enable Accelmed to deploy significant capital into its portfolio companies. The firm typically commits between $20 million and $50 million per company, indicating a preference for substantial investments in more mature, commercial-stage enterprises rather than early-stage startups.

Accelmed's investment approach is hands-on, providing strategic and operational expertise to help companies scale their market penetration and product adoption. Headquartered in New York, New York, Accelmed also maintains an office in Herzliya, Israel, reflecting a global outlook and a particular interest in both the robust U.S. and Israeli medtech ecosystems. Their focus remains steadfast on innovative medical device companies that are past the initial research and development phase and are ready for significant commercialization and growth.